Translational Solutions to Target Oncology Drug Resistance

The evolving cancer resistance landscape requires a comprehensive approach to identify and target new therapeutic opportunities. This includes leveraging translatable and clinically relevant models such as patient-derived xenografts (PDX) and organoids, as well as biomarker-driven strategies and in vitro assays that reflect patient clinical situations from the earliest stages of preclinical development.

With the expansion of Immuno-Oncology (I/O) drug development, the use of advanced I/O co-culture in vitro assays becomes critical for testing the efficacy and safety of new I/O targets. Additionally, the deployment of diverse, clinically-predictive in vivo models, including PDX and organoids, is essential to evaluate new therapies, discover and validate predictive biomarkers, and stratify patient populations with precision before transitioning to clinical trials.

Join us to explore how integrating these cutting-edge tools, including patient-derived systems and I/O co-culture assays, can accelerate the development of therapies aimed at overcoming oncology drug resistance.

Register Now

Attendance is free, lunch will be served, and a drinks reception will follow after the event. Spaces are limited. We encourage you to register early.

Speakers